Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus VALSARTAN.
AVALIDE vs VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Valsartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
80-320 mg orally once daily; initial dose typically 80 mg or 160 mg once daily.
None Documented
None Documented
Clinical Note
moderateValsartan + Torasemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide."
Clinical Note
moderateValsartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid."
Clinical Note
moderateValsartan + Furosemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide."
Clinical Note
moderateValsartan + Bumetanide
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Terminal elimination half-life is approximately 6 hours (range 4–9 hours) in healthy adults. In patients with hepatic impairment, half-life is similar due to lack of significant metabolism.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Primarily eliminated unchanged in feces (83%) via biliary excretion, and approximately 13% in urine as unchanged drug. Renal clearance accounts for ~30% of total clearance.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB
"The risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide."